Co-crystals of non-steroidal anti-inflammatory drugs (NSAIDs): Insight toward formation, methods, and drug enhancement

Página do item simplificado
dc.contributor.authorNascimento, André L.C.S. [UNESP]
dc.contributor.authorFernandes, Richard P. [UNESP]
dc.contributor.authorCharpentier, Maxime D.
dc.contributor.authorter Horst, Joop H.
dc.contributor.authorCaires, Flávio J. [UNESP]
dc.contributor.authorChorilli, Marlus [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversity of Strathclyde
dc.date.accessioned2021-06-25T11:15:20Z
dc.date.available2021-06-25T11:15:20Z
dc.date.issued2021-10-01
dc.description.abstractPharmaceutical co-crystals have been explored by many researchers as a strategy to optimize physicochemical properties of solid-state drugs. Their improvements of solubility, bioavailability, and the reduced tendency for phase transformation occurrence, are factors that highlight benefits of pharmaceutical co-crystals among other solid forms. According to the Biopharmaceutical Classification System (BCS), non-steroidal anti-inflammatory drugs (NSAIDs) are class II drugs, which have low aqueous solubility and therefore co-crystallization has the potential to optimize NSAID product properties. In this review, we highlight the recent progress made on NSAIDs co-crystals, their co-formers, synthesis, methods and use, while we underline some promising results on in vitro and in vivo co-crystal properties. A celecoxib-tramadol co-crystal reaches phase III clinical trials, showing greater analgesic activity than both individual APIs. The aqueous solubility of the co-crystal formed between L-proline and diclofenac is very high in comparison with the pure drug. Naproxen co-crystals with urea and thiourea have an increase of drug release of almost 60%. Co-crystal design brings a new perspective in drug development since the co-former used can also be a biologically active component allowing to combine different anti-inflammatory drugs, which have an incredible spectrum of application due to the analgesic, anti-pyretic and anti-inflammatory properties.en
dc.description.affiliationSão Paulo State University (UNESP) School of Pharmaceutical Sciences
dc.description.affiliationSão Paulo State University (UNESP) Institute of Chemistry
dc.description.affiliationEPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation University of Strathclyde
dc.description.affiliationSão Paulo State University (UNESP) School of Sciences
dc.description.affiliationUnespSão Paulo State University (UNESP) School of Pharmaceutical Sciences
dc.description.affiliationUnespSão Paulo State University (UNESP) Institute of Chemistry
dc.description.affiliationUnespSão Paulo State University (UNESP) School of Sciences
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipEngineering and Physical Sciences Research Council
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.format.extent227-241
dc.identifierhttp://dx.doi.org/10.1016/j.partic.2021.03.015
dc.identifier.citationParticuology, v. 58, p. 227-241.
dc.identifier.doi10.1016/j.partic.2021.03.015
dc.identifier.issn2210-4291
dc.identifier.issn1674-2001
dc.identifier.scopus2-s2.0-85105089298
dc.identifier.urihttp://hdl.handle.net/11449/208635
dc.language.isoeng
dc.relation.ispartofParticuology
dc.sourceScopus
dc.subjectBioavailability
dc.subjectCo-crystal discovery
dc.subjectNSAIDs
dc.subjectPharmaceutical co-crystals
dc.subjectSupramolecular synthons
dc.titleCo-crystals of non-steroidal anti-inflammatory drugs (NSAIDs): Insight toward formation, methods, and drug enhancementen
dc.typeArtigo

Arquivos

Coleções

Artigos - Fármacos e Medicamentos - FCFAR